The Efficacy of Claritin in Healthy Subjects

The University of Chicago

Status and phase

Completed

Phase 4

Conditions

Healthy

Treatments

Drug: Claritin

Study type

Interventional

Funder types

Other

Identifiers

NCT01451996

16171A

Details and patient eligibility

About

The primary goal of this study is to examine determinants of the efficacy of Claritin.

Full description

Subjects will be given Claritin 10mg tablet. Subjects will be challenged with histamine via skin prick prior to Claritin administration and at 1 and 2 hours post administration. We will measure and record wheal and flare area 10 minutes following each challenge.

Enrollment

340 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria.

Males and females between 18 and 65 years of age.

Exclusion Criteria.

Pregnant or lactating women.
Upper respiratory infection within 14 days of study start.
Women of childbearing potential not using specific contraception method(s) (i.e., birth control pills, depo Provera, double barrier) as well as women who are breastfeeding.
Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study (heart, lung, kidney, neurological, oncologic or liver disease).
Use of any other investigational agent in the last 30 days.
Use of medications that may affect skin testing. Specifically, subjects are excluded if they have used an antihistamine during the 4 days preceding their treatment visit.